Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
---|---|---|---|---|---|
Net Income | -- | 6.03M | -1.48M | -3.48M | -5.71M |
Total Depreciation and Amortization | -- | 27.10K | 27.60K | 26.50K | 24.70K |
Total Amortization of Deferred Charges | -- | 105.20K | 92.20K | 80.70K | 70.70K |
Total Other Non-Cash Items | -- | 161.70K | -1.15M | 241.00K | 104.90K |
Change in Net Operating Assets | -- | -1.64M | 779.50K | 701.30K | 3.65M |
Cash from Operations | -- | 4.69M | -1.72M | -2.43M | -1.86M |
Capital Expenditure | -- | 0.00 | -15.10K | 0.00 | -14.40K |
Sale of Property, Plant, and Equipment | -- | 300.00 | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -65.30K | -24.30K | -72.00K | -64.50K |
Cash from Investing | -- | -65.00K | -39.40K | -72.00K | -78.90K |
Total Debt Issued | -- | 300.00K | -- | 0.00 | 1.00M |
Total Debt Repaid | -- | -504.50K | -200.50K | -64.70K | 0.00 |
Issuance of Common Stock | -- | 643.80K | -- | 0.00 | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | 1.10M | -- | 0.00 | 6.17M |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -54.60K | -- | -35.10K | -963.30K |
Cash from Financing | -- | 1.48M | -200.50K | -99.80K | 6.21M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -- | 6.11M | -1.96M | -2.60M | 4.27M |